Reversible White-Matter Lesions Reported in Down Syndrome: Longitudinal Imaging Findings

A recent report on longitudinal brain MRI in adults with Down syndrome described trajectories in white matter hyperintensities (WMH) that were not uniformly progressive and, in a subset of participants, decreased over time. WMH are lesions typically associated with cerebral vascular alterations and are often considered a marker of small-vessel disease; the authors noted they have frequently been interpreted as permanent or irreversible, yet serial imaging showed that some WMH can fluctuate and even decrease in this population. The report framed WMH volume change as bidirectional, with increases, stability, and decreases all observed across scans.

The report described a cohort including adults with Down syndrome and a neurotypical control group (80 and 53 participants, respectively), with at least two MRI examinations per person. Investigators assessed annual WMH volume change using scans separated by a minimum of six months and described heterogeneous trajectories over an approximate two- to three-year interval, including measurable reductions in some individuals. Reductions were reported as more pronounced once clinical Alzheimer’s symptoms had begun, compared with earlier clinical stages and controls. Regionally, decreases were described as most evident in parietal and occipital lobes and in periventricular areas. Overall, the findings were presented as showing WMH burden as a variable feature that can shift within individuals over follow-up rather than tracking a single monotonic course.

The report also described imaging correlates and biomarker analyses intended to help contextualize why reductions might appear. The presence of cerebral microbleeds was described as being associated with greater longitudinal WMH reduction, an observational link the authors connected to cerebral amyloid angiopathy as a vascular context for MRI-visible signal change. When investigators examined Alzheimer’s disease biomarkers in cerebrospinal fluid and plasma, the report stated that longitudinal WMH change did not show robust significant associations with biomarker changes in this analysis.

The authors outlined several hypotheses for why WMH volume might decrease in some circumstances, while keeping mechanistic interpretation explicitly provisional. Proposed contributors included neurodegeneration-related white-matter atrophy that could alter apparent lesion volume, transient inflammatory processes that could fluctuate over time, and amyloid angiopathy–related vascular leakage that could generate MRI signal changes that later diminish. In the same discussion, the report noted an interpretive consideration for trials: because WMH volume may naturally increase or decrease over time, longitudinal radiologic changes in clinical trials of anti-amyloid therapies may be more difficult to interpret when vascular-related imaging alterations are also tracked. The authors said that knowing these lesions can show natural fluctuations “requires us to be highly precise in clinical trials” when interpreting longitudinal radiologic changes. In the report’s framing, MRI lesion trajectories were described as potentially reflecting multiple interacting processes whose timing may not be strictly linear.

Key Takeaways:

• Investigators reported dynamic WMH trajectories in adults with Down syndrome, including measurable reductions in a subset, described as more pronounced after clinical Alzheimer’s symptoms began.
• The report described an association between microbleeds and greater WMH reduction, while noting that longitudinal WMH change did not show robust significant associations with CSF or plasma Alzheimer’s biomarkers in the analysis.
• Authors proposed neurodegeneration-related atrophy, transient inflammation, and cerebral amyloid angiopathy–related vessel-barrier alteration with fluid leakage as potential explanations, and they discussed how natural WMH fluctuations can complicate interpretation of MRI changes over time in anti-amyloid therapy trials.